Story perspectives

Promising Lung Cancer Therapies Show High Response Rates

9/8/2025

Summary

Story summary

Researchers presented promising results for ifinatamab deruxtecan (I-DXd) at the 2025 World Conference on Lung Cancer.
The Phase 2 IDeate-Lung01 trial reported a 48.2% objective response rate and an 87.6% disease control rate in heavily pretreated patients.
SHR-4849, targeting DLL3, showed a 59.5% objective response rate in its Phase 1 trial.
Both therapies address significant unmet needs in extensive-stage small cell lung cancer (ES-SCLC).
Ongoing studies will refine dosing and explore biomarkers for personalized lung cancer treatment.

1 of 1

Story summary

Researchers presented promising results for ifinatamab deruxtecan (I-DXd) at the 2025 World Conference on Lung Cancer.
The Phase 2 IDeate-Lung01 trial reported a 48.2% objective response rate and an 87.6% disease control rate in heavily pretreated patients.
SHR-4849, targeting DLL3, showed a 59.5% objective response rate in its Phase 1 trial.
Both therapies address significant unmet needs in extensive-stage small cell lung cancer (ES-SCLC).
Ongoing studies will refine dosing and explore biomarkers for personalized lung cancer treatment.